The UK鈥檚 healthcare regulator the Medicines and Healthcare products Regulatory Agency聽(MHRA) has approved mRNA Covid-19 vaccine for temporary and emergency use in adults. Previously known as mRNA-1273, the product is now referred to as COVID-19 Vaccine Moderna.

惭辞诲别谤苍补鈥檚 candidate is the third Covid-19 vaccine to be approved in the UK. Pfizer/BioNTech鈥檚 mRNA vaccine, BNT162b2, was approved on 2 December, while the AstraZeneca/Oxford adenovirus candidate was approved on 30 December.

According to a detailed about the approval, the MHRA has recommended that the second dose of this vaccine should be administered 28 days after the first dose. This suggests the Moderna vaccine will not be subject to the up to 12-week dose gap recommended by the MHRA for the other two UK approved vaccines.

The decision was made based on a rolling review of 惭辞诲别谤苍补鈥檚 clinical trial data, which began in October last year, and on the recommendation of the Commission on Human Medicines. 聽惭辞诲别谤苍补鈥檚 Covid-19 vaccine has demonstrated 94.1% efficacy against Covid-19 in a Phase III clinical trial.

Moderna CEO St茅phane Bancel noted: 鈥淲e appreciate the confidence shown by the聽UK聽MHRA in Covid-19 Vaccine Moderna with this decision, which marks an important step forward in the global fight against Covid-19.

MHRA聽chief executive Dr June Raine said: 鈥淭oday鈥檚 approval brings more encouraging news to the public and the healthcare sector. Having a third Covid-19 vaccine approved for supply following a robust and thorough assessment of all the available data is an important goal to have achieved and I am proud that the agency has helped to make this a reality.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

鈥淭he progress we are now making for vaccines on the regulatory front, whilst not cutting any corners, is helping in our global fight against this disease and ultimately helping to save lives. I want to echo that our goal is always to put the protection of the public first.鈥

The UK had already negotiated access to seven million doses of 惭辞诲别谤苍补鈥檚 vaccine, but as a result of the approval, the UK has exercised its option to purchase an additional ten million doses. Reports suggest that supplies are not expected until spring once Moderna has increased its manufacturing capacity.

The UK approval also marks the fifth approval for 惭辞诲别谤苍补鈥檚 Covid-19 vaccine in the world. The vaccine has already been approved in the US, Canada, Israel and the European Union.